<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854072</url>
  </required_header>
  <id_info>
    <org_study_id>KG 4/2015</org_study_id>
    <nct_id>NCT02854072</nct_id>
  </id_info>
  <brief_title>A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients</brief_title>
  <official_title>A Prospective, Randomized, Open-label, Multicenter, Parallel Design, Phase III Study to Assess the Efficacy and Safety of GV1001 Concurrent With Gemcitabine/Capecitabine Versus Gemcitabine/Capecitabine Alone in Treating Locally Advanced and Metastatic Pancreatic Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess treatment of GV1001 concurrent with Gemcitabine/Capecitabine versus
      Gemcitabine/Capecitabine alone in locally advanced and metastatic pancreatic cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a phase III, prospective, randomized, open-label, multicenter
      clinical trial comparing GV1001 concurrent with Gemcitabine/Capecitabine versus
      Gemcitabine/Capecitabine alone in treating locally advanced and metastatic pancreatic cancer
      patients. Patients will be treated until disease progression and will be subject to follow-up
      until death.

      Patients will be randomized equally between the two arms:

        1. Gemcitabine and Capecitabine

        2. GV1001+ Gemcitabine and Capecitabine
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression (TTP)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>one year</time_frame>
    <description>Objective response rate assesses by CT scan (RECIST and irRC criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit response (CBR)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response with eotaxin level (baseline of serum eotaxin level, pg/mL)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using EORTC QLQ-C30</measure>
    <time_frame>up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using EQ-5D-3L</measure>
    <time_frame>up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CA19-9 (Serum cancer antigen) over time</measure>
    <time_frame>one year</time_frame>
    <description>Cancer antigen 19-9 (CA 19-9) is used to help differentiate between cancer of the pancreas and other conditions, as well as to monitor treatment response and recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to the NCI CTCAE v4.03</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>GV1001 + gemcitabine/capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>gemcitabine/capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GV1001</intervention_name>
    <description>At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.</description>
    <arm_group_label>GV1001 + gemcitabine/capecitabine</arm_group_label>
    <other_name>Tertomotide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.</description>
    <arm_group_label>GV1001 + gemcitabine/capecitabine</arm_group_label>
    <arm_group_label>gemcitabine/capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 830 mg/m^2 will be orally given in the morning and evening (total dose of 1660 mg/m^2) for 21 days followed by 7 days' rest.</description>
    <arm_group_label>GV1001 + gemcitabine/capecitabine</arm_group_label>
    <arm_group_label>gemcitabine/capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 19 years

          2. Histologically or cytologically proven pancreatic ductal adenocarcinoma carcinoma or
             undifferentiated carcinoma of the pancreas.

          3. Locally advanced or metastatic disease precluding curative surgical resection or
             patients who have relapsed following previously resected pancreatic cancer.

          4. Contrast enhanced CT scan of the thorax, abdomen and pelvis within 28 days (and up to
             a maximum of 32 days) prior to commencing treatment.

          5. Unidimensionally measurable disease (from CT scan) in accordance with the RECIST
             guidelines.

          6. ECOG performance status 0, 1 or 2.

          7. Adequate organ function as determined by the following laboratory values:

               -  Platelets ≥100 x 10^9 /L

               -  WBC ≥ 3 x 10^9 /L

               -  ANC ≥1.5 x 10^9 /L

               -  Serum total bilirubin ≤ 2.0 mg/dL

               -  CCr (Cockcroft &amp; Gault) &gt; 50 mL/min

          8. Life expectancy ≥ 90 days

          9. Fully informed written consent given.

        Exclusion Criteria:

          1. Brain metastasis or meningeal carcinomatosis.

          2. Clinically significant serious disease or organ system disease not currently
             controlled on present therapy.

          3. Previous chemotherapy for locally advanced and metastatic disease. Previously adjuvant
             chemotherapy for resected pancreatic cancer will be permitted providing chemotherapy
             was completed more than 12 months previously.

          4. Radiotherapy within the last 8 weeks prior to start of study treatment.

          5. Concurrent malignancies or invasive cancers diagnosed within the past 5 years except
             for adequately treated basal cell carcinoma of the skin, in situ carcinoma of the
             uterine cervix or resected pancreatic cancer.

          6. Medication which might affect immunocompetence e.g. chronic treatment with long term
             steroids or other immunosuppressant for an unrelated condition. Patients will be
             eligible if they have been receiving short term steroids for palliation of cancer
             related symptoms.

          7. Administration of medicines from other clinical trials within 8 weeks from
             registration.

          8. Pregnancy or breast feeding.

          9. Uncontrolled angina pectoris.

         10. Known malabsorption syndromes.

         11. Patients with a known hypersensitivity to any of the investigational products or
             patients with a dihydropyrimidine dehydrogenase (DPD) deficiency.

         12. All men or women of reproductive potential, unless using at least two contraceptive
             precautions, one of which must be a condom.

         13. Investigator's judgment against participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Si Young Song, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong-Tae Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ho Soon Choi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University Seoul Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ho Gak Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daegu Catholic University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Sik Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Woo Choi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gwang Ha Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kwang Hyuck Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Hee Cho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joung-Ho Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seung Ok Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang-Hwan Park, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eun Kwang Choi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeju National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyong Joo Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonju Severance Christian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Yong Cho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo Jin Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Park</last_name>
    <email>hpark@kaelgemvax.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoon Jin Lee</last_name>
    <email>yjlee@kaelgemvax.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheongbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joung-Ho Han, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju-si</city>
        <state>Gangwon-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyong Joo Lee, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woo Jin Lee, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju-si</city>
        <state>Jeju-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Kwang Choi, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Ok Lee, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwang Ha Kim, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Gak Kim, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Woo Choi, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Hwan Park, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hee Cho, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Yong Cho, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Soon Choi, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Sik Lee, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwang Hyuck Lee, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-Tae Kim, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si Young Song, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>November 20, 2016</last_update_submitted>
  <last_update_submitted_qc>November 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GV1001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

